Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR0951)
Name
Anti-PD-1 antibody
Synonyms
Anti-programmed cell death-1 (anti-PD-1)
    Click to Show/Hide
Disease Hepatocellular carcinoma [ICD-11: 2C12] Approved [1]
Lung cancer [ICD-11: 2C25] Approved [1]
Melanoma [ICD-11: 2C30] Approved [1]
Stomach cancer [ICD-11: 2B72] Approved [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Curcumin      Hellenia speciosa     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression F2  Molecule Info 
Pathway MAP
Up-regulation Expression IFNG  Molecule Info 
Pathway MAP
Down-regulation Expression IL10  Molecule Info 
Pathway MAP
Down-regulation Expression IL4  Molecule Info 
Pathway MAP
Down-regulation Expression MDC  Molecule Info 
Pathway MAP
Down-regulation Expression TGFB1  Molecule Info 
Pathway MAP
Up-regulation Expression TNF  Molecule Info 
Pathway MAP
                    In-vitro Model Hep 3B2.1-7 CVCL_0326 Childhood hepatocellular carcinoma Homo sapiens
CSQT-2 CVCL_M183 Adult hepatocellular carcinoma Homo sapiens
                    In-vivo Model Hep3B cells was subcutaneously injected into the left axilla of each five-week-old healthy BALB/c female nude mice.
                    Experimental
                    Result(s)
Curcumin had a synergistic effect with anti-PD-1 to slow Hep3B cell proliferation, activate lymphocytes, inhibit immune evasion, and down-regulate TGF-beta1 expression.
          Lycopene      Daucus carota     Click to Show/Hide the Molecular Data of This NP
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Up-regulation Expression IFNG  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation JAK-2  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation STAT3  Molecule Info 
Pathway MAP
                    In-vivo Model Lewis lung carcinoma (LLC) cells (1*106) were injected in the rear flak of C57BL/6 mice.
                    Experimental
                    Result(s)
Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells.
Target and Pathway
Target(s) Complement decay-accelerating factor (CD55)  Molecule Info  [4]
TNF-related apoptosis-inducing ligand (TRAIL)  Molecule Info  [4]
KEGG Pathway Cytokine-cytokine receptor interaction Click to Show/Hide
2 FoxO signaling pathway
3 Apoptosis
4 Natural killer cell mediated cytotoxicity
5 Measles
6 Influenza A
7 Complement and coagulation cascades
8 Hematopoietic cell lineage
9 Viral myocarditis
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 IL4 Signaling Pathway
3 TGF_beta_Receptor Signaling Pathway
4 TNFalpha Signaling Pathway
5 Leptin Signaling Pathway
6 IL5 Signaling Pathway
7 FSH Signaling Pathway
Panther Pathway Apoptosis signaling pathway Click to Show/Hide
Pathway Interaction Database TRAIL signaling pathway Click to Show/Hide
2 Caspase Cascade in Apoptosis
Reactome Ligand-dependent caspase activation Click to Show/Hide
2 Regulation by c-FLIP
3 RIPK1-mediated regulated necrosis
4 CASP8 activity is inhibited
5 Dimerization of procaspase-8
6 TRAIL signaling
7 Class B/2 (Secretin family receptors)
8 Regulation of Complement cascade
WikiPathways Apoptosis Click to Show/Hide
2 Extrinsic Pathway for Apoptosis
3 Apoptosis Modulation and Signaling
4 TP53 Network
5 Complement and Coagulation Cascades
6 Complement Activation, Classical Pathway
7 Human Complement System
8 GPCR ligand binding
9 Complement cascade
References
Reference 1 FDA Approved Drug Products from FDA Official Website.
Reference 2 Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. Life Sci. 2021 Mar 19;279:119359.
Reference 3 Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell Int. 2019 Mar 21;19:68.
Reference 4 Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model. Mol Med Rep. 2017 Dec;16(6):9375-9382.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China